Add-on therapies Diacomit (stiripentol) and Fintepla (fenfluramine) were found to be more effective for seizure control in Dravet syndrome patients than Epidiolex (cannabidiol) in a recent indirect analysis of clinical trial data. Overall, Diacomit was best for stopping seizures altogether, and was associated with fewer treatment…
News
From honoring those lost to Dravet syndrome to sharing facts on social media, supporters are marking Dravet Syndrome Awareness Month, observed each June to call attention to the genetic disorder that affects an estimated one in 20,000 to 40,000 individuals globally. International Dravet Syndrome Awareness Day is June…
Treatment with add-on Diacomit (stiripentol) rapidly reduced seizure frequency and extended seizure-free periods in children with Dravet syndrome, according to additional data from the treatment’s STICLO clinical trials. Open-label extension study data, which had not been previously reported, showed that placebo-treated patients who switched to Diacomit experienced a…
Epygenix Therapeutics, the company developing EPX-100 (clemizole) as a potential add-on treatment for people with Dravet syndrome, has been acquired by Harmony Biosciences. “This acquisition builds on our leadership position in sleep/wake and our franchise in neurobehavioral disorders, allowing us to leverage our expertise in CNS…
Avata Biosciences is gearing up for a Phase 3 clinical trial to test SAP-021, the company’s oral capsule formulation of cannabidiol — commonly abbreviated as CBD — that’s being developed as an alternative to Epidiolex, an oil-based cannabidiol solution that’s approved to reduce seizure frequency in people with…
Among recent treatments to reduce the risk of seizures in people with Dravet syndrome, Fintepla (fenfluramine) appears to be the most potent, according to a new analysis. “In [Dravet syndrome], [Fintepla] provided significantly greater efficacy compared with other [anti-seizure medications], and it was generally well tolerated,” researchers wrote…
New treatment approaches, such as gene therapies, that aim to restore the activity of SCN1A, the gene often defective in Dravet syndrome patients, must remain active throughout adulthood to adequately maintain brain function, a lab study suggests. Using a Dravet mouse model, the work showed that activating a…
The severity of seizures was reduced among Dravet syndrome patients in the U.K. over 10 years, but developmental outcomes worsened, a recent analysis shows. Children younger than age 6 generally tended to see a worse trajectory during that period than older patients, including having a higher burden of coexisting…
Avicanna has launched a new version of its proprietary oral cannabidiol (CBD) formulation, called RHO Phyto Micro Drop 10, in Canada. The new product will be available to certain Canadian patients, including individuals with seizures, who have medical authorization through a medical cannabis care platform, according to a…
Treatment with the investigational therapy STK-001 led to significant reductions in seizure frequency and clinically meaningful improvements in cognition and behavior for children and adolescents with Dravet syndrome, according to data from Phase 1/2 studies and their open-label extensions (OLEs). Developer Stoke Therapeutics said that the findings…
Recent Posts
- Dravet patients face heavy seizure burden despite medications: Study
- My late daughter’s dog dealt with grief alongside our family
- Dravet behavior, social issues emerge in toddlerhood, study finds
- A winter storm reminds me of magical snow days with Austen
- Online parent coaching helps Dravet kids build independence
- Cell study offers new clues to Dravet seizure triggers
- Epidiolex reduces seizures in rare Dravet syndrome cases: Study
- Faster-than-expected enrollment seen in trial testing zorevunersen for Dravet
- The little lost journal that brings back memories of our Dravet journey
- FDA grants breakthrough status to new gene therapy for Dravet syndrome